N/A N=20 An MRI Study of the Sniffing, Neutral and Extended Head and Neck Positions
Intubation, Intratracheal
Primary: Angle A Measured on MRI — 20.7; 10.8; 30.0 degree
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=73 Game Plan for PrEP
Human Immunodeficiency Virus Exposure · Alcohol; Harmful Use
Primary: Pre-exposure Prophylaxis (PrEP) Lapse Days — 3; 3 Participants
Phase 2 N=80 Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos
Cigarette Smoking
Primary: Percentage of Participants Achieving Biochemically Verified 7-day Point Prevalence Abstinence at 3 Months — 10; 24; 29; 16 Participants
Phase 2 N=58 Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
Thrombotic Microangiopathies
Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants
Phase 2 N=80 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Metastatic Pancreatic Adenocarcinoma
Primary: Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 Criteria — 1; 8 Participants
N/A N=257 Benefits of µCor in Ambulatory Decompensated Heart Failure
Heart Failure
Primary: Correlation of μCor Readings to Heart Failure Related Clinical Events — 34; 173; 16; 22 participants
N/A N=64 Cortical Contributions to Motor Sequence Learning
Brain Injuries
Primary: Serial Reaction Time Task (SRTT) Performance — 31; 35; 38; 24 milliseconds (ms)
Phase 3 N=124 Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading…
N/A N=66 Do Generic Volar Locking Plates Provide Similar Outcomes at a Reduced Cost?
Distal Radius Fractures
Primary: 90-day Reoperation Rate — 0; 0 Participants
N/A N=945 Effect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChart
Health Care Utilization
Primary: Number of Participants Who Completed Well Child Check Visit — 40; 76; 61 Participants — p=0.000
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
N/A N=1 Optimization of VNS in Epileptic Patients to Induce Cardioprotection
Epilepsy · Sudden Cardiac Death
Primary: Change in Seizure Frequency or Duration Via a Routine Seizure History Used in Clinical Practice.
N/A N=57 Comparison of Traditional, Web-based or a Combined Cardiac Rehabilitation Programme
Cardiovascular Diseases
Primary: Change From Baseline Energy Expenditure (Measured in METs Using the BACPR Conversion Chart) and After 8 Weeks of Intervention. — 5.9; 5.8; 5.6; 7.4 score on a scale
N/A N=74 Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Hidradenitis Suppurativa · Surgical Wound
Primary: Wound QOL Survey Score Over Time — 1.14; 0.94; 0.77; 0.66 score on a scale
Phase 4 N=337 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Cushing's Disease · Acromegaly · Neuroendocrine Tumors
Primary: Incidence of Adverse Events to Evaluate Long Term Safety Data — 265; 102; 127; 39 participants